Introduction {#s1}
============

Systemic sclerosis (SSc; scleroderma) is an autoimmune disease characterized by widespread skin and internal organ fibrosis. With a standardized mortality ratio of 3.5 ([@bib11]), SSc has the highest mortality among major rheumatic diseases ([@bib10]; [@bib51]). This high disease burden in SSc is driven partly by only modest response of its fibrotic features to immunosuppressive agents ([@bib21]; [@bib50]). Mechanisms leading to the excessive fibrosis remain elusive, which has contributed to the fact that there are no US Food and Drug Administration--approved medications for skin or internal organ fibrosis in SSc. Thus, this disease remains fatal for many patients. The differentiation of myofibroblasts and the excessive production of collagen I (COL(I)) and other extracellular matrix (ECM) proteins are the pathological hallmarks of SSc skin ([@bib2]). An activation of TGFβ, a multifunctional cytokine critical for wound healing and tissue repair, has been implicated in SSc pathogenesis ([@bib24]). However, the signals responsible for the sustained activation and amplification of myofibroblasts and accumulation of ECMs are not well understood, representing a fundamental knowledge gap in our understanding of SSc pathology. Specifically, it is unknown which mediator amplification mechanisms are responsible for the exaggerated response to profibrotic cytokines.

Cleavage and polyadenylation is a pre-mRNA--processing step that completes the maturation of eukaryotic mRNAs and is required for mRNA stability, nuclear export, and efficient translation ([@bib7]). Cleavage and polyadenylation was once thought to be a constitutive process, but recent discoveries indicate this biological process is tightly regulated. In fact, a majority of mammalian genes contain more than one polyadenylation signal (PAS). Differential utilization of alternative PASs by the cleavage/polyadenylation machinery results in transcripts with variable 3′UTR tail lengths and occurs through a process known as alternative polyadenylation (APA; [@bib8]; [@bib13]). Through APA, the 3′UTR length of a given mRNA can often vary in different tissues, cell cycle stages, and genetic backgrounds. In normal cells, there is a tendency for mRNAs to use a distal PAS (dPAS) located the greatest distance downstream of the stop codon. However, the proximal PAS is largely used in highly proliferating cells, leading to transcript isoforms with a shorter 3′UTR ([@bib12]; [@bib38]). Given that the majority of human microRNAs (miRNAs) target the 3′UTR, a switch from dPAS to proximal PAS substantially reduces the number of miRNA-binding sites ([@bib26]; [@bib27]). This switch establishes a potential scenario where a shortened 3′UTR can evade miRNA-mediated gene repression and consequently increase protein expression. Over the past few years, the importance of APA has been highlighted in several pathological states, including malignancies and cardiac disorders ([@bib6]; [@bib29]; [@bib41]; [@bib45]; [@bib52]; [@bib56]).

Recently, the mammalian cleavage factor I 25-kD subunit (CFIm25; encoded by the gene *NUDT21*) was discovered as a master regulator of APA among 15 cleavage and polyadenylation factors ([@bib15]; [@bib23]; [@bib29]). However, it is unknown whether CFIm25 plays a role in the pathogenesis of skin fibrosis.

In this study, we investigated the role of the key APA regulator, CFIm25, in SSc-related dermal fibrosis. Our data demonstrated that CFIm25 levels were decreased in SSc skin and primary dermal fibroblasts. Following coimmunofluorescence and in vitro cell culture study, we further determined that CFIm25 was also downregulated in (myo)fibroblasts of fibrotic skin. Furthermore, using an unbiased, novel RNA sequencing (RNA-seq) technology, we demonstrated that depletion of *CFIm25* in dermal fibroblasts was directly associated with 3′UTR shortening and increased translation of key profibrotic genes and ECMs. Moreover, 3′UTR shortening was confirmed in several key TGFβ-regulated profibrotic genes in the SSc skin. Consistent with these findings, we also observed that genetic deletion of *CFIm25* in fibroblasts leads to increased ECM deposition in murine dermal fibrosis models, while overexpression (OE) of *CFIm25* promotes the 3′UTR lengthening of key fibrotic genes and attenuates bleomycin-induced skin fibrosis. Overall, our study systematically identified a novel role for CFIm25and APA in SSc pathogenesis.

Results {#s2}
=======

*CFIm25*is downregulated in human fibrotic skin and is selectively decreased in (myo)fibroblasts {#s3}
------------------------------------------------------------------------------------------------

First, we mined our previously published global gene expression data attained from arm skin biopsies from 61 SSc patients and 36 age-, gender-, and ethnicity matched controls. These data indicated that SSc patients had significantly lower *CFIm25* (gene name: *NUDT21*) mRNA level ([@bib1]; [Fig. 1 A](#fig1){ref-type="fig"}). Moreover, patients with disease duration \<2 yr (representing the early and active subset of disease; [@bib30]; [@bib47]) had significantly lower *CFIm25* mRNA levels than late-stage patients (P = 0.009; [Fig. 1 B](#fig1){ref-type="fig"}). Next, we investigated CFIm25 expression in human skin collected from 10 SSc patients and 10 matched controls by dual immunohistochemistry. [Table S1](#tblS1){ref-type="table"} shows the demographic and clinical characteristics of participants in the immunohistochemistry experiments. CFIm25 was ubiquitously expressed in the nucleus of the majority of the cells in normal skin ([Fig. 1 C](#fig1){ref-type="fig"}, arrowheads, red), but was decreased in α smooth muscle actin (α-SMA)--positive (α-SMA^+^) myofibroblasts in SSc skin ([Fig. 1 C](#fig1){ref-type="fig"}, arrows, green). Blinded cell counting indicated that the percentage of CFIm25-positive (CFIm25^+^) fibroblasts was significantly decreased in SSc fibroblasts ([Fig. 1 D](#fig1){ref-type="fig"}). Further analysis showed that the majority of α-SMA^+^ cells are CFIm25 negative ([Fig. S1 B](#figS1){ref-type="fig"}) and the majority of CFIm25-negative (CFIm25^−^) cells are α-SMA positive ([Fig. S1 C](#figS1){ref-type="fig"}). Although the percentage of CFIm25^−^/α-SMA^+^ fibroblasts over total α-SMA^+^ fibroblasts was not changed in SSc skin ([Fig. S1 B](#figS1){ref-type="fig"}), the absolute number of CFIm25^−^α-SMA^+^ cells was significantly increased ([Fig. 1 E](#fig1){ref-type="fig"}). These findings suggest that CFIm25 is mainly downregulated in α-SMA^+^ cells, and it is downregulated in SSc skin possibly due to an overall increase in the number of α-SMA^+^ cells in the dermal layer. Consistent with these observations, CFIm25 protein expression was dramatically downregulated in primary fibroblasts isolated from SSc skin compared with those from normal skin ([Figs. 1 F](#fig1){ref-type="fig"} and S1 D). Together, these data show that *CFIm25* is downregulated in SSc skin and fibroblasts relative to normal skin and fibroblasts.

###### Demographic and clinical characteristics of participants in the immunohistochemistry experiments

                                                  SSc (*n* = 10)   Control (*n* = 10)
  ----------------------------------------------- ---------------- --------------------
  Age (yr), mean (SD)                             41.18 (16.99)    45.15 (15.18)
  Female gender, n (%)                            6 (60%)          6 (60%)
  Disease duration, mean (SD)                     2.49 (0.94)      N/A
  Skin score at the site of biopsy, mean (SD)     2.1 (0.32)       N/A
  Overall modified Rodnan skin score, mean (SD)   26.7 (6.88)      N/A

N/A, not applicable.

![***CFIm25* is depleted in myofibroblasts of SSc skin. (A)** Comparison of *CFIm25* transcript levels in 61 SSc and 36 matched controls (shown as log-transformed signal intensity) indicates significant *CFIm25* downregulation in SSc. **(B)** *CFIm25* transcript levels in the skin of early and late Ssc patients (*n* = 54). The y axis in A and B indicates the log2-transformed signal intensity of *CFIm25*. Data were analyzed using a Student's *t* test. **(C)** Dual immunostainings show CFIm25 (red) and α-SMA (green) expression in normal and SSc skin (*n* = 10). Arrowheads show CFIm25-positive cells, and arrows point to myofibroblasts; nuclei are blue. Scale bars = 50 µm. **(D)** The percentage of CFIm25^+^ fibroblasts were counted and calculated. **(E)** The number of CFIm25^−^ and α-SMA^+^ cells were counted. P value was calculated using two-tailed Student's *t* test to determine the difference between normal and SSc cells. **(F)** CFIm25 protein expression was examined in primary fibroblasts derived from five unaffected controls and five SSc patients. For A and B, data are presented as box and whisker plot showing quartiles and range. For D and E, data are mean ± SEM and representative of two experiments with *n* = 10 per group. Data were analyzed using a Student's *t* test; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181384_Fig1){#fig1}

![**Dual immunostaining was performed for CFIm25 and α-SMA expression in normal and SSc skin (*n* = 10).** **(A)** The number of CFIm25 and α-SMA double-positive cells was calculated for each sample. **(B)** The percentages of CFIm25^−^ and α-SMA^+^ cells in all α-SMA^+^ cells were counted and calculated. **(C)** The percentages of CFIm25^−^ and α-SMA^+^ cells in all CFIm25^−^ fibroblasts were counted and calculated. **(D)** The densitometry of CFIm25 and COL(I) were measured. P values were determined by a two-tailed Student's *t* test to determine the difference between normal and SSc cells. Data are presented as mean ± SEM and representative of two experiments with *n* = 10 per group (A--C) and two experiments with *n* = 5 per group (D). Data were analyzed using Student's *t* test. \*, P \< 0.05; \*\*\*, P \< 0.001.](JEM_20181384_FigS1){#figS1}

RNA-seq identifies important fibrotic pathways targeted by *CFIm25* {#s4}
-------------------------------------------------------------------

The functional consequence of *CFIm25* suppression on fibroblast activation and ECM production is not known. To systematically identify genes directly targeted by *CFIm25*, RNA-seq was performed to determine the global APA profile of five normal human dermal fibroblasts (HDFs) in response to *CFIm25* depletion. As shown in [Fig. 2, A and B](#fig2){ref-type="fig"}, 971 genes (8.1%) showed significant shortening in their 3′UTR in response to *CFIm25* knockdown (KD), while only 93 genes (0.7%) showed significant lengthening. Next, an unbiased Ingenuity analysis of predicted upstream regulators of the genes with shortened 3′UTRs was conducted. This analysis revealed TGFβ as the top upstream regulating growth factor/cytokine (P = 6.82 × 10^−3^), followed by angiotensinogen, Angiopoietin 2, and fibroblast growth factor ([Fig. 2 C](#fig2){ref-type="fig"}). Specifically, 97 TGFβ-regulated genes showed 3′UTR shortening upon *CFIm25* KD in dermal fibroblasts. The list of genes with shortened 3′UTRs upon *CFIm25* KD can be found on our website (<https://www.uth.tmc.edu/scleroderma/>).

![**RNA-seq of *CFIm25* KD versus control in normal HDFs (*n* = 5).** **(A)** Representative scatterplot of PDUIs in control and *CFIm25* KD cells where mRNAs are significantly shortened (*n* = 971) or lengthened (*n* = 93) after *CFIm25* KD in five HDFs. **(B)** Pie graph showing 971 (8.1%) genes had shortened 3′UTR, while only 93 (0.7%) genes showed 3′UTR lengthening. **(C)** TGF-β pathway was predicted to be the top upstream regulator of the *CFIm25* KD APA profile, followed by angiotensinogen, Angiopoietin 2, and fibroblast growth factor pathways.](JEM_20181384_Fig2){#fig2}

Notably, a similar predicted upstream growth factor/cytokine analysis in our previously published large SSc skin gene expression dataset also identified TGFβ as the most activated upstream regulator ([@bib1]), supporting a link between *CFIm25* and SSc pathogenesis. Cumulatively, these data support that *CFIm25* is a key regulator of fibrotic pathways through its APA regulation in HDFs.

Removing *CFIm25* is sufficient to promote profibrotic factor and ECMs expression through APA {#s5}
---------------------------------------------------------------------------------------------

Due to the importance of the TGFβ pathway in skin fibrosis and SSc pathogenesis ([@bib24]), we chose four CFIm25 targeted genes involved in this pathway to confirm the results of RNA-seq: *COL1A1*, *TGFBR1*, *COL11A1*, and *SPARC*. In addition, these four genes had increased transcript expression in SSc skin in our global gene expression data ([@bib1]). We first performed Western blot analysis to determine whether the protein expression of these four genes is increased altered following *CFIm25* depletion. As shown in [Figs. 3 A](#fig3){ref-type="fig"} and S2, COL(I) (including COL1A1 and COL1A2), TGFBR1, and COL11A1 showed enhanced protein levels in all five fibroblast cell lines, and secreted protein acidic and cysteine-rich (SPARC) protein expression was increased in four out of five fibroblasts upon successful *CFIm25* depletion ([Fig. 3 A](#fig3){ref-type="fig"}). To confirm whether the increased protein expression was resulting from APA, we next used a real-time quantitative PCR (RT-qPCR)--based method to monitor the usage of the dPAS of *COL1A1*, *TGFBR1*, *COL11A1*, and *SPARC*. Briefly, two pairs of primers were designed, with one targeting the open reading frame of transcripts to represent the total transcript level and the other targeting sequences just before the dPAS to detect long transcripts that used the dPAS ([Fig. 3 B](#fig3){ref-type="fig"}, upper panel). A normalized dPAS usage was calculated as ΔΔCT, with a negative value indicating the mRNA has 3′UTR shortening compared with the control. All four genes showed decreased dPAS usage (i.e., 3′UTR shortening) in *CFIm25* KD fibroblasts compared with the control siRNA ([Fig. 3 B](#fig3){ref-type="fig"}, lower panel), demonstrating that depletion of *CFIm25* directly leads to the 3′UTR shortening of all four genes. Concomitant with 3′UTR shortening, the transcript levels of all four genes were increased ([Fig. 3, C and D](#fig3){ref-type="fig"}) in *CFIm25*-depleted skin fibroblasts. Taken together, these data further confirm that *CFIm25* depletion alone is sufficient to regulate APA and enhance the TGFβ pathway and COL(I) synthesis.

![**KD of *CFlm25* induces APA and upregulation of fibrotic factors in normal HDFs.** Five primary normal HDFs were transfected with *CFlm25* specific siRNA (si\_*CFIm25*) or a si-RNA control. **(A)** Western blot confirmed effective KD of CFlm25 and showed increased protein levels of COL(I), TGFBR1, COL11A1, and SPARC. **(B)** The upper panel demonstrates the primer locations for monitoring APA, and the lower panel demonstrates normalized dPAS usage by RT qPCR showing 3′UTR shortening upon *CFIm25* KD. **(C--F)** RT-qPCR demonstrates increased *COL1A1, TGFBR1*, *COL11A1*, and *SPARC* transcript levels in *CFIm25* KD HDFs. Data are mean ± SEM of *n* = 3 independent experiments (five primary cell lines and two biological replications). P values were determined using a one-sample *t* test comparing to 0 (B) or a paired two-tailed Student's *t* test comparing si_CFIm25 to si_Con (C--F). \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20181384_Fig3){#fig3}

Key TGFβ-regulated fibrotic genes show 3′UTR shortening in SSc skin {#s6}
-------------------------------------------------------------------

The above in vitro experiments suggest that *CFIm25* depletion promotes APA of important profibrotic genes. To extend our findings to SSc skin in comparison to matched unaffected controls, we performed RT-qPCR assays in the above four, TGFβ-regulated, verified *CFIm25*-targeted genes. We conducted the dPAS usage analysis in 10 SSc-affected skin samples obtained from patients with early diffuse cutaneous involvement and 10 age- and gender-matched controls. [Table S2](#tblS2){ref-type="table"} shows the demographic and clinical characteristics of participants in these experiments. This analysis revealed that all four genes, *COL1A1*,*COL11A1*,*TGFBR1*, and*SPARC*, had 3′UTR shortening in SSc skin ([Fig. 4 A](#fig4){ref-type="fig"}). The overall transcript levels of *COL1A1*,*COL11A1*, and*SPARC* were also increased in SSc skin. Although *TGFBR1* transcript levels were numerically higher in SSc skin, this difference did not reach statistical significance ([Fig. 4 B](#fig4){ref-type="fig"}). Taken together, key *CFIm25* regulated profibrotic genes, including *COL1A1*, exhibit 3′UTR shortening in SSc skin, underscoring the potential role of this RNA-processing factor in SSc pathogenesis.

###### Demographic and clinical characteristics of participants in the dPAS experiments

                                                  SSc (*n* = 10)   Control (*n* = 10)
  ----------------------------------------------- ---------------- --------------------
  Age (yr), mean (SD)                             54.81 (7.94)     52.88 (7.7)
  Female gender, *n* (%)                          5 (50%)          5 (50%)
  Disease duration, mean (SD)                     1.18 (0.71)      N/A
  Skin score at the site of biopsy, mean (SD)     2.3 (0.48)       N/A
  Overall modified Rodnan skin score, mean (SD)   27.5 (5.54)      N/A

N/A, not applicable.

![**APA of *CFIm25* targets was present in SSc skin. (A)** Normalized dPAS usage performed by RT-qPCR showing *COL1A1*, *COL11A1*, *TGFBR1*, and *SPARC* had 3′UTR shortening in affected skin collected from SSc patients. *n* = 10. \*\*, P \< 0.01 versus 0. **(B)** The transcript levels of above four genes were analyzed using RT-qPCR. Data are presented as mean ± SEM and representative of *n* = 10 patients (two biological replications). P values were calculated using a one-sample *t* test compared with 0 (A) or a paired two-tailed Student's *t* test (B). \*, P \< 0.05; \*\*, P \< 0.01. ns, not significant.](JEM_20181384_Fig4){#fig4}

CFIm25 is downregulated in mouse skin fibrosis {#s7}
----------------------------------------------

We next sought to understand whether a similar mechanism was involved in mouse models of skin fibrosis in vivo. S.c. bleomycin administration is a widely used inflammation-driven dermal fibrosis model ([@bib58]; [@bib59]). In this model, 8-wk-old female mice were treated with repeated s.c. bleomycin injections (0.02 U/mice, injected six times a week for 4 wk). Mice treated with the same amount of PBS were used as controls. Similar to the findings in human tissue, CFIm25 protein expression was decreased in the skin of bleomycin-injected mice ([Figs. 5 B](#fig5){ref-type="fig"} and S3 A) and was also downregulated in dermal myofibroblasts ([Fig. 5 A](#fig5){ref-type="fig"}, arrows, red). Moreover, we also examined CFIm25 levels in skin fibrosis in a second dermal fibrosis model, the tight skin 1 (TSK1) mouse model. In this model, spontaneous skin fibrosis results from a tandem duplication within the fibrillin-1 gene ([@bib42]). A similar CFIm25 downregulation was observed in the skin of TSK1 mice ([Figs. 5 C](#fig5){ref-type="fig"} and S3 B). Overall, our data suggest that CFIm25 downregulation is a common feature in human SSc and murine dermal fibrosis.

![**CFIm25 is decreased in murine dermal fibrosis. (A)** Immunohistochemistry showing CFIm25 (brown) and α-SMA (red) staining in the skin of mice subcutaneously treated with PBS or bleomycin (*n* = 10). Arrowheads show CFIm25^+^ cells, and arrows point to α-SMA^+^ myofibroblasts. Scale bars = 25 µm. **(B and C)** CFIm25 protein expression was determined in the skin lysate from (B) mice injected with PBS or bleomycin; and (C) 8- to 10-wk-old WT and TSK1 mice. COL(I) was used as a marker for fibrosis.](JEM_20181384_Fig5){#fig5}

KO of *CFIm25* in fibroblasts exaggerates dermal fibrosis {#s8}
---------------------------------------------------------

Based on the finding that *CFIm25* KD promotes activation of the TGFβ pathway and COL(I) synthesis, we further investigated whether *CFIm25* depletion in vivo affects bleomycin-induced skin fibrosis. We generated homozygous Col1a1-creER^T2^-*CFIm25*^f/f^ mice to conditional KO *CFIm25* expression in Col1a1 expression cells, including fibroblasts. 6-wk-old Col1a1-creER^T2^-*CFIm25*^f/f^ and control Col1a1-creER^T2^ mice were injected with tamoxifen for 5 d to induce Cre activation. As shown in [Figs. 6 A](#fig6){ref-type="fig"} and S4 A, Cre was successfully expressed in dermal fibroblasts of Col1a1-creER^T2^-*CFIm25*^f/f^ and control Col1a1-creER^T2^ mice, and CFIm25 expression was dramatically suppressed in Col1a1-creER^T2^-*CFIm25*^f/f^ fibroblasts. Of note, although the used promoter in this strain (2.3-kb proximal Col1a1) has been shown to be active in osteoblasts and odontoblasts ([@bib22]; [@bib37]; [@bib43]), we did not observe any dental or bone abnormalities 4 wk after Cre-activation (data not shown), possibly due to the fact that the Cre-activation occurred in adult mice. 1 wk after the last tamoxifen injection, mice were treated with repeated s.c. bleomycin to induce skin fibrosis. COL(I) protein levels ([Figs. 6 B](#fig6){ref-type="fig"} and S4 B), as well as dermal thickness ([Fig. 6, C and D](#fig6){ref-type="fig"}), were increased in bleomycin-treated mice, suggesting dermal fibrosis was successfully induced in our model. Notably, CFIm25 protein expression was slightly decreased in the skin of PBS-treated Col1a1-creER^T2^-*CFIm25*^f/f^ mice compared with controls, and it was further downregulated in the conditional KO mice treated with bleomycin, possibly due to the activation and amplification of fibroblasts upon bleomycin treatment ([Fig. 6 B](#fig6){ref-type="fig"}). Interestingly, COL(I) expression was already increased in the Col1a1-creER^T2^-*CFIm25*^f/f^ mice without bleomycin treatment, and it was further increased in the Col1a1-creER^T2^-*CFIm25*^f/f^ mice upon treatment with bleomycin ([Fig. 6 B](#fig6){ref-type="fig"}). Although TGFBR1 and COL11A1 protein levels did not differ in the PBS group between the knockout and control mice, they were enhanced in *CFIm25* depleted mice in the bleomycin group ([Figs. 6 B](#fig6){ref-type="fig"} and S4 B). In parallel, dermal thickness was also further increased in *CFIm25* KO mice treated with bleomycin ([Fig. 6, C and D](#fig6){ref-type="fig"}), indicating that depletion of *CFIm25* in fibroblasts potentiates bleomycin-induced dermal fibrosis. We have previously shown that *Col1a1*,*Tgfbr1*, and *Col11a1* are directly targeted by *CFIm25* in HDFs and show 3′UTR shortening in SSc skin. To understand whether similar mechanisms are involved in mice, we checked the dPAS usage of these three genes and found all three genes had 3′UTR shortening in the skin of Col1a1-creER^T2^-*CFIm25*^f/f^ mice treated with bleomycin ([Fig. 6 E](#fig6){ref-type="fig"}). Of note, we could not investigate the dPAS usage in SPARC, the other above-investigated key profibrotic transcript, because SPARC lacks the annotation to APA in mice. Cumulatively, these data suggest that *CFIm25* depletion in fibroblasts potentiates dermal fibrosis by regulating the APA of profibrotic factors/ECMs and enhancing their translation.

![**Knocking out *CFIm25* in fibroblasts promotes dermal fibrosis and APA.** 6- to 8-wk-old Col1a1-creER^T2^ and Col1a1-creER^T2^-*CFIm25*^f/f^ mice were treated with tamoxifen for 5 d to induce Cre activation. **(A)** Western blot shows Cre expression and a downregulation of *CFIm25* in primary fibroblasts isolated from Col1a1-creER^T2^-*CFIm25*^f/f^ mice (*n* = 4). Tamoxifen-treated mice were then administrated with s.c. PBS/bleomycin 6 d a week for 4 wk (*n* = 10). **(B)** Western blot was performed to confirm the downregulation of CFIm25 and the upregulation of fibrotic makers in skin of PBS/bleomycin-treated Col1a1-creER^T2^ and Col1a1-creER^T2^-*CFIm25*^f/f^ mice. **(C)** Masson's trichrome showing dermal fibrosis in different treatment groups; the data are quantitated in D. Scale bars = 125 µm. **(E)** The dPAS usage for *Col1a1, Tgfbr1*, and *Col11a1* was determined using RT-qPCR. Data are mean ± SEM and were analyzed using one-way ANOVA followed by a Sidak\'s multiple comparisons test (D) or unpaired two-tailed Student's *t* test (E). *n* = 2 independent experiments (six to eight mice per group, two biological replications). \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181384_Fig6){#fig6}

*CFIm25* OE attenuates fibrotic protein expression in skin fibroblasts {#s9}
----------------------------------------------------------------------

To understand whether the fibrotic phenotype of *CFIm25* KD can be reversed by *CFIm25* OE, we constructed a *CFIm25* OE lentivirus using the pLV-EF1a-IRES-Puro Vector that contains a human elongation factor-1 α (EF-1a) promoter upstream of an internal ribosome entry site (IRES) element to coexpress puromycin marker. The human *CFIm25* coding domain sequence (CDS) was placed between the EF-1a and IRES. The IRES allows the expression of CFIm25 and puromycin marker from a single mRNA, thus ensuring the coexpression of CFIm25 and puromycin marker in the same cells. A successful CFIm25 OE ([Fig. 7 A](#fig7){ref-type="fig"}) and 3′UTR lengthening of *CFIm25* target genes *COL1A1, TGFBR1, COL11A1*, and *SPARC* ([Fig. 7 B](#fig7){ref-type="fig"}) were detected in skin fibroblasts infected with *CFIm25* OE lentivirus. Consistent with 3′UTR lengthening, the protein levels of COL1A1, COL11A1, and SPARC were decreased 3 d after *CFIm25* OE in skin fibroblasts ([Fig. 7 A](#fig7){ref-type="fig"}). Overall, our data indicate that fibrotic protein expression can be suppressed by augmenting the expression of *CFIm25*.

![***CFIm25* OE lentivirus promotes 3′UTR lengthening and inhibits protein translation of profibrotic factor and ECMs in skin fibroblasts.** Two HDFs were infected with control or *CFIm25*-overexpressing lentivirus at 25 MOI. **(A)** Western blots were performed to determine *CFIm25* OE 2 d after lentivirus infection, and the expression of COL(I), TGFBR1, COL11A1 and SPARC 3 d after lentivirus infection. **(B)** The dPAS usage of *COL1A1*, *TGFBR1*, *COL11A1*, and *SPARC* were determined in HDFs infected with lentivirus for 3 d. Data are presented as mean log~2~ (percentage of long transcript in *CFIm25*-overexpressing cells/percentage of long transcript in control cells) ± SEM; *n* = 3 independent experiments (two cell lines, two biological replications). P value was determined using a one-sample *t* test versus 0. \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20181384_Fig7){#fig7}

*CFIm25* OE attenuates bleomycin-induced skin fibrosis {#s10}
------------------------------------------------------

To further investigate the ability of *CFIm25* OE to impact APA and skin fibrosis in mice, 6-wk-old female C57BL6 mice were injected with GFP or CFIm25-IERS-GFP OE lentivirus s.c. 1 wk before, 1 wk after, and 3 wk after the initial s.c. bleomycin injection. *CFIm25* OE lentivirus significantly increased dermal *CFIm25*transcript and protein levels ([Figs. 8 A](#fig8){ref-type="fig"} and S5 B) and inhibited the expression of COL(I), fibronectin, TGFBR1, COL11A1, and SPARC ([Figs. 8 A](#fig8){ref-type="fig"} and S5 C). dPAS analysis demonstrated that *Col1a1, Tgfbr1*, and *Col11a1* underwent 3′UTR lengthening ([Fig. 8 B](#fig8){ref-type="fig"}). Although *Sparc* had no APA in *CFIm25* overexpressing skin, its protein levels were decreased possibly due to an indirect regulation. In parallel with these findings, the pepsin-soluble collagen levels ([Fig. 8 C](#fig8){ref-type="fig"}), skin thickness ([Fig. 8, D and E](#fig8){ref-type="fig"}), number of α-SMA positive cells ([Fig. 8 F](#fig8){ref-type="fig"}), and picrosirius red--stained area ([Fig. 8 G](#fig8){ref-type="fig"}) were significantly reduced in skin infected with *CFIm25* OE lentivirus. Taken together, these data suggest that *CFIm25* OE attenuates bleomycin-induced skin fibrosis in mice.

![***CFIm25* OE prevents bleomycin-induced skin fibrosis**. 6-wk-old mice were injected with s.c. GFP or CFIm25-IRES-GFP--overexpressing lentivirus (10 × 10^7^ PFU/ml, 50 µl per spot) 1 wk before, 1 wk after, and 3 wk after the first bleomycin injection, and mice were injected with repeated s.c. bleomycin six times a week for 4 wk. Skin was collected 28 d after the first bleomycin injection for analysis. **(A)** Western blot was performed to determine the expression of CFIm25, COL(I), fibronectin (FN), TGFBR1, COL11A1, and SPARC. **(B)** The dPAS usage of *Col1a1*, *Tgfbr1*, and *Col11a1* was determined. Data are presented as log~2~ (percentage of long transcript in *CFIm25*-overexpressing skin/percentage of long transcript in control skin). **(C)** Sircol assay was performed to determine the pepsin-soluble collage levels in skin. **(D)** Masson's trichrome, α-SMA, and picrosirius red staining showing dermal fibrosis in different treatment groups. Scale bars =125 µm. **(E)** Histological dermal thickness. **(F)** The numbers of α-SMA^+^ fibroblasts per field (left panel) as well as the percentage of α-SMA^+^ fibroblasts over the total fibroblasts (right panel). **(G)** The percentage of picrosirius red--stained area was measured, and data are presented as fold change to GFP control. Data are mean ± SEM of *n* = 2 independent experiments (five mice per group; C, D, F, and G) with two biological replications (B). P value was determined using one sample *t* test (B) or unpaired two-tailed Student's *t* test (C, D, F, and G). \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20181384_Fig8){#fig8}

Discussion {#s11}
==========

The present study evaluated the role of *CFIm25* as an important APA regulator in skin fibrosis. Our data demonstrate a consistent downregulation of *CFIm25* in skin samples collected from SSc patients, and this downregulation was mainly detected in (myo)fibroblasts. RNA-seq detected significant APA events in human skin fibroblasts upon *CFIm25* KD and identified important fibrotic TGFβ-regulated genes targeted by *CFIm25*. Moreover, we demonstrated that key verified *CFIm25*-targeted fibrotic genes have shortened 3′UTRs in affected SSc skin. Similar *CFIm25* downregulation was also observed in mouse models of skin fibrosis. Lastly, transgenic mice with *CFIm25* depletion in fibroblasts had exaggerated skin fibrosis, while *CFIm25* restoration attenuated skin fibrosis in mouse. Taken together, our findings characterized a previously unknown importance of CFIm25 in skin fibrosis and link a novel role of APA to SSc pathogenesis.

To our knowledge, this is the first study to link APA and its key regulator, CFIm25, to dermal fibrosis. The role of APA as a RNA regulation process has been reported in various human physiological conditions and diseases. Transcripts with longer 3′UTRs were observed during embryonic development ([@bib19]) and neuron differentiation ([@bib40]), as well as the development of the central nervous system ([@bib17]; [@bib44]). Several recent studies have shown that global 3′UTR shortening is present in malignancies ([@bib56]; [@bib57]) and is associated with poorer prognosis in breast and lung cancers ([@bib25]). Disease-specific APA signatures in numerous genes are also identified in cardiac disorders ([@bib6]). APA also contributes to key immunological responses, including B cell differentiation ([@bib49]) and T cell activation ([@bib5]), as well as lipopolysaccharide-stimulated macrophages ([@bib39]). In addition, APA plays an important role in cellular processes, including cell proliferation ([@bib12]; [@bib38]; [@bib46]), cell fate determination ([@bib3]; [@bib18]), and cell senescence ([@bib16] *Preprint*). In the current study, we observed that *CFIm25*, an important APA regulator, was downregulated in SSc skin, as well as in murine dermal fibrosis models. Moreover, several key fibrotic genes, including *COL1A1* ([@bib20]), *COL11A1*, *TGFBR1*, and *SPARC*, showed significant 3′UTR shortening in affected SSc skin. These four genes had increased transcript levels in our previous SSc skin gene expression study and have been implicated in SSc pathogenesis ([@bib20]; [@bib24]; [@bib60]). Cumulatively, our findings uncovered APA as a novel amplification mechanism for the exaggerated dermal fibrosis in SSc.

Important functions for *CFIm25* through regulating APA have been reported in several cellular processes. *CFIm25* depletion promoted neurite outgrowth ([@bib14]), enhancing cancer cell proliferation through upregulating oncogenes ([@bib4]; [@bib29]; [@bib48]), inhibiting cancer cell apoptosis ([@bib61]), increasing hepatocellular carcinoma metastasis ([@bib54]), controlling *Entamoeba histolytica* parasite ([@bib32]), and facilitating the generation of induced pluripotent stem cells and impairing the differentiation of myeloid precursors and embryonic stem cells ([@bib3]). In the present study, *CFIm25* expression was downregulated in fibrotic skin, and this downregulation was mainly observed in (myo)fibroblasts, the key cells producing excessive ECM in skin fibrosis, suggesting that *CFIm25* and APA are linked to the pathogenesis of skin fibrosis. Indeed, skin fibroblasts with *CFIm25* KD have increased collagen production and enhanced key fibrotic protein expression. Consistent with our overall hypothesis, *CFIm25* depletion in murine dermal fibroblasts led to exaggerated skin fibrosis upon s.c. bleomycin administration. Moreover, OE of *CFIm25* promoted the 3′UTR lengthening of fibrotic markers and inhibited their expression and eventually attenuated skin fibrosis. In summary, our findings indicate a novel function of *CFIm25* in the pathogenesis of skin fibrosis.

*CFIm25*-mediated suppression of gene expression is mainly performed through a widespread distal-to-proximal switch of PASs ([@bib3]; [@bib23]; [@bib29]). Consistent with findings in other cell types ([@bib3]; [@bib29]; [@bib48]), we demonstrated for the first time using a global, unbiased RNA-seq approach that *CFIm25* KD in dermal fibroblasts leads to 3′UTR shortening in 971 transcripts and 3′UTR lengthening in only 93 transcripts. The shortened transcripts can be more stable as they evade 3′UTR-regulating factors, including miRNAs, and hence enhancing their protein translation. Indeed, we verified that *COL1A1*, *CO11A1*, *TGFBR1*, and *SPARC*, four fibrotic genes involved in the TGFβ pathway, had 3′UTR shortening and elevated protein expression upon *CFIm25* KD. The other function of 3′UTR shortening of target genes could be releasing miRNAs and RNA-binding proteins that would have been bound to the longer form, thus resulting in the redistribution of RNA-binding proteins and miRNA ([@bib34]). However, it should be noted that 3′UTR shortening does not lead to increased protein translation in all genes ([@bib3]). The missing correlation between 3′UTR shortening and protein abundance in some genes could depend on the availability of miRNAs and RNA regulatory factors in various cells. That also explains why *CFIm25* depletion has a different impact on various cells, including cancer cells, stem cells, immune cells, and skin fibroblasts. In the present study, we focused on dermal fibroblasts, the key cell type for the observed exaggerated ECM deposition in SSc skin.

An unbiased, global Ingenuity Pathway Analysis (IPA) predicted TGFβ1 as the top upstream regulator of the 971 genes that showed 3′UTR shortening upon *CFIm25* depletion. Specifically, 97 out of these 971 (∼10%) *CFIm25*-targeted genes can be regulated by TGFβ1, including key fibrotic genes known to play a role in SSc pathogenesis such as collagens, integrins ([@bib36]), TGFBR1 ([@bib33]), and SPARC ([@bib2]; [@bib24]; [@bib60]). Consistent with this prediction, TGFβ1 was the top predicted regulator for SSc skin gene expression signature in our previous global gene expression studies ([@bib1]). Moreover, our skin immunostaining experiments indicated that CFIm25 is specifically downregulated in (myo)fibroblasts of patients with SSc, a cell type prominently targeted by TGFβ1, suggesting that *CFIm25* depletion might function as an enhancing mediator of TGFβ1 response in SSc dermal fibroblasts. TGFβ1 is a master regulator of fibrotic diseases that drives fibroblast proliferation, myofibroblast differentiation, and ECM synthesis ([@bib24]). TGFβ1 mainly functions through TGFBR1 and TGFBR2 to activate receptor signaling ([@bib31]). We found *TGFBR1*, as well as TGFβ1 target genes *COL1A1*, *COL11A1*, and *SPARC*, had 3′UTR shortening and enhanced protein expression in *CFIm25*-depleted fibroblasts, suggesting that *CFIm25* depletion is sufficient to activate TGFβ1 signaling. Consistent with this notion, *CFIm25* depletion in fibroblasts in a bleomycin-induced murine dermal fibrosis model led to 3′UTR shortening of the same key TGFβ1-regulated genes (*Col1a1*, *Tgfbr1*, and *Col11a1*) and enhanced their protein expression and resulted ultimately in increased fibrotic response. In summary, our data suggest that TGFβ1 is an upstream regulator of the *CFIm25* depletion signature, and downregulation of *CFIm25* in turn promotes TGFβ1 signaling and enhances skin fibrosis.

Although our data indicate that TGFβ1 is a key upstream regulator of the *CFIm25* depletion signature, future studies are needed to examine the mechanistic link between TGFβ1 and *CFIm25* depletion. Moreover, considering the diverse function of *CFIm25* in different cell types, it will be instructive to elucidate the role of *CFIm25* in other type of cells, such as immune cells, involved in SSc pathogenesis. In addition to *CFIm25* studied here, there are other proteins that can also modulate APA. For example, two other components of the CFIm complex, CFIm59 and CFIm68, also promote the usage of dPAS sites, and depletion of CFIm68 causes widespread distal-to-proximal PAS shifting ([@bib28]; [@bib29]). Although our study demonstrates for the first time an important role for APA in SSc pathogenesis focusing on *CFIm25* mediating 3′UTR shortening, it may prove useful to investigate the role of other APA regulators in fibrosis and SSc pathogenesis in future studies.

SSc is an enigmatic disease with no US Food and Drug Administration--approved medications and the highest mortality rate among major rheumatic diseases. Herein, we link for the first time a recently discovered key regulator of RNA processing to the exaggerated dermal fibrosis in SSc. Specifically, the downregulation of the RNA-processing factor *CFIm25* leads to 3′UTR shortening of key TGFβ-regulated profibrotic genes and exaggerated skin fibrosis. Methods aimed at *CFIm25* rescue can be a potential therapeutic target in this devastating fibrotic disease.

Materials and methods {#s12}
=====================

Human samples {#s13}
-------------

Skin biopsy samples were collected from the Genetic versus Environment In Scleroderma Outcome Study cohort at the University of Texas Health Science Center at Houston and age-, gender-, and ethnicity matched controls. All patients fulfilled the 2012 American College of Rheumatology/European League Against Rheumatism Classification Criteria ([@bib53]) and had diffuse cutaneous involvement, disease duration \<3.5 yr at enrollment, and affected skin at the site of skin biopsy. The healthy control subjects had no personal or family medical history of autoimmune diseases. Biopsy samples (3-mm punch) were obtained from the ulnar, dorsal aspect of the forearm around the proximal one-third junction. All subjects provided written informed consent, and the study was approved by the institutional review boards at the University of Texas Health Science Center.

Mice {#s14}
----

Mice were housed in pathogen-free conditions at the University of Texas Health McGovern Medical School, Houston, TX. All experiments were approved by the University of Texas Health Animal Welfare Committee. All mice were on the C57BL/6J background. WT, Col1a1-Cre (B6.Cg-Tg(Col1a1-cre/ERT2)1Crm/J), and TSK1 mice were purchased from Jackson Laboratory. *CFIm25^f/f^* mice were generated using floxed alleles designed to delete exons 2 and 3 of the *CFlm25* gene (*CFIm25*^f/f^; Ozgene). To induce Cre recombination to knockout *CFIm25* specifically in fibroblasts, 6-wk-old transgenic mice (*CFIm25^f/f^* Col1a1-Cre) or age- and gender-matched littermate controls (Col1a1-cre) were i.p. injected with 75 mg/kg/d tamoxifen for 5 d ([@bib9]; [@bib35]). To induce skin fibrosis, the mice were administrated with repeated s.c. bleomycin (0.02 U/mice/d, injected six times a week for 4 wk). The first injection of bleomycin was administered 7 d after the end of tamoxifen treatment.

Immunohistochemistry and immunofluorescence {#s15}
-------------------------------------------

Mouse or human skin was dehydrated, paraffin embedded, and sectioned (4 µm). Sections were rehydrated, quenched with 3% hydrogen peroxide, incubated in citric buffer (VectorLabs) for antigen retrieval, and blocked with Avidin/Biotin Blocking System (VectorLabs) and then 5% normal goat serum.

For double immunohistochemistry staining for CFIm25 and α-SMA, sections were incubated with antibodies for CFIm25 (1:400; Proteintech) overnight at 4°C and then with biotinylated anti-Rabbit antibodies (1:1,000; VectorLabs) for 1 h at room temperature and ABC Elite streptavidin reagents for 30 min at room temperature. Slides were then developed with 3,3-diaminobenzidine (Sigma-Aldrich). After development, the slides were incubated with mouse anti-α-SMA antibodies (1:1,000; Sigma-Aldrich) overnight at 4°C, anti-mouse secondary antibodies (1:1,000; VectorLabs) and alkaline phosphatase ABC Elite streptavidin reagents and developed using Vector Red Substrate (VectorLabs).

For CFIm25/α-SMA immunofluorescence dual staining, skin sections were first stained with CFIm25 and developed with Vecto Red Substrate. The sections were then blocked with normal horse serum and incubated with anti-α-SMA antibodies and Alexa Fluor 488 Goat Anti-Mouse IgG (Life Technologies). Slides were finally mounted with ProLong Gold Antifade Mountant with DAPI (Life Technologies).

Masson's trichrome and picrosirius red staining {#s16}
-----------------------------------------------

Paraffin-embedded skin slides were rehydrated and stained with Masson's trichrome (Sigma-Aldrich) or picrosirius red kit (Abcam). The thickness of the dermis, defined as the distance between the epidermal-dermal junction to the dermal-adipose layer junction, was measured blindly at six randomly selected sites/microscopic fields in each skin sample ([@bib55]). The picrosirius red--stained skin was quantified using ImageJ and macro language (available at <https://imagej.nih.gov/ij/docs/examples/stained-sections/index.html>). The percentage of positive picrosirius red--stained area was determined, and data were normalized to the GFP control.

Cell culture and transfection {#s17}
-----------------------------

Primary human skin fibroblasts were isolated using an outgrowth model from skin punch from normal donor and SSc patients. Isolated fibroblasts were treated in DMEM (Sigma-Aldrich) containing 10% fetal bovine serum and 1% antibiotics to avoid contamination, and mycoplasma infection was tested using the MycoAlert Mycoplasma Detection Kit (Lonza). Cell culture was maintained at 37°C in a humidified 5% carbon dioxide atmosphere.

To knock down *CFIm25*, fibroblasts were transfected with 50 ng/ml *CFIm25* or control siRNA (Sigma-Aldrich) using Lipofectamine RNAiMAX (ThermoFisher Scientific) on day 0 and day 1, and RNA and protein were collected on day 4 for analysis.

RT-qPCR {#s18}
-------

Total RNA was extracted using RNeasy Mini Kit (Qiagen) and reverse-transcribed using iScript Reverse Transcription Supermix (Bio-Rad). Real-time PCR was performed under Lightcycler 96 (Roche), and data were quantified using the comparative Ct method and presented as mean ratio to β-actin or 18s rRNA.

The APA of target genes was determined using a previously described PCR-based method ([@bib29]). For each candidate gene, two pairs of primers were designed with one targeting the open reading frame to represent the total transcript level and the other targeting sequences just before the dPAS to detect long transcripts that used the dPAS ([Fig. 3 B](#fig3){ref-type="fig"}). Percentage of dPAS usage was calculated as ΔCT = CT~distal~ − CT~total~. Data were presented as fold changes normalized to control by calculating ΔΔCT = ΔCT~average\ target~ − ΔCT~average\ of\ control~. A negative ΔΔCT value indicates the mRNA has 3′UTR shortening compared with controls, and this approach has been used to quantify APA ([@bib29]). The primers used for this study are listed in [Table S3](#tblS3){ref-type="table"}.

###### Primers used for RT-qPCR

  Gene                Forward primer (5′--3′)          Reverse primer (5′--3′)
  ------------------- -------------------------------- -------------------------------------
  Homo_CFIm25         TGA​AGT​TGA​AGG​ACT​AAA​ACG​CT   ACC​AGT​TAC​CAA​TGC​AAT​CGT​C
  Homo_COL1A1         GTG​CGA​TGA​CGT​GAT​CTG​TGA      CGG​TGG​TTT​CTT​GGT​CGG​T
  Homo_COL1A1 Long    GTG​AGG​GAG​ACA​GAC​ACC​TG       GTG​TTC​TGG​GGA​TTC​AGG​AG
  Homo_TGFBR1         ACG​GCG​TTA​CAG​TGT​TTC​TG       GCA​CAT​ACA​AAC​GGC​CTA​TCT​C
  Homo_TGFBR1 Long    TTT​GTG​CAG​GAT​TCT​TTA​GGC​TT   GGC​TTC​TCA​GTA​TCA​TTC​GAC​TT
  Homo_SPARC          TGA​GGT​ATC​TGT​GGG​AGC​TAA​TC   CCT​TGC​CGT​GTT​TGC​AGT​G
  Homo_SPARC Long     CAA​GCC​CAG​CAC​TAG​TCT​CA       TGG​TCT​GCC​TGC​TAG​AAT​GT
  Homo_COL11A1        ACC​CTC​GCA​TTG​ACC​TTC​C        TTT​GTG​CAA​AAT​CCC​GTT​GTT​T
  Homo_COL11A1 Long   TCT​CCT​TGT​TTT​CAG​TGT​GCT​T    AGT​CCA​CCA​TAT​GTT​ATT​CAT​TTA​GCA
  Mus_COL1A1          GCT​CCT​CTT​AGG​GGC​CAC​T        CCA​CGT​CTC​ACC​ATT​GGG​G
  Mus_COL1A1 Long     GGC​AAT​GCT​GAA​ATG​TCC​CA       ACA​GTC​CAA​GAA​CCC​CAT​GT
  Mus_COL1A2          AAG​GGT​GCT​ACT​GGA​CTC​CC       TTG​TTA​CCG​GAT​TCT​CCT​TTG​G
  Mus_COL2A1          GGG​AAT​GTC​CTC​TGC​GAT​GAC      GAA​GGG​GAT​CTC​GGG​GTT​G
  Mus_TGFBR1          TCT​GCA​TTG​CAC​TTA​TGC​TGA      AAA​GGG​CGA​TCT​AGT​GAT​GGA
  Mus_TGFBR1 Long     TAC​GTC​AGA​AAC​ACC​ATG​GGA      ACA​AAG​GCC​CCA​AAA​GTA​CC
  Mus_FN1             GCT​CAG​CAA​ATC​GTG​CAG​C        CTA​GGT​AGG​TCC​GTT​CCC​ACT
  Mus_ACTA1           GGC​TGT​ATT​CCC​CTC​CAT​CG       CCA​GTT​GGT​AAC​AAT​GCC​ATG​T
  Homo_ACTA1          CAT​GTA​CGT​TGC​TAT​CCA​GGC      CTC​CTT​AAT​GTC​ACG​CAC​GAT

RNA-seq and data analysis {#s19}
-------------------------

Total RNA-seq was performed by HiSeq 2000 (Novogene) using the poly(A) enrichment method. This allowed us to obtain a precise and complete snapshot of the transcriptome and enabled the identification of transcript expression as well as APA. Paired-end RNA-seq was performed to yield a minimum of 80 million reads per sample. Raw sequence data have been deposited in the Gene Expression Omnibus database (accession no. [GSE137276](GSE137276)). RNA-seq gene expressions were quantified by RSEM. To identify genes undergoing APA upon *CFIm25* depletion, a well-established algorithm DaPars (<https://github.com/ZhengXia/DaPars>; [@bib56]) was used to predict the proximal APA site and estimate the abundance of long and short forms of 3′UTRs, and then the percentage of distal polyadenylation site usage index (PDUI) was calculated for each transcript. Briefly, DaPars uses a linear regression model to predict the proximal APA site and estimates the abundance of long-form and short-form 3′UTRs and then calculates the PDUI. For the comparison between si_RNA- and si\_*CFIm25*--transfected fibroblasts, genes with a difference of PDUI ≥0.15 in at least three HDFs were considered to have APA.

To identify upstream regulator cytokines/growth factors, the list of genes with significant 3′UTR shortening upon *CFIm25* depletion was uploaded into IPA. The goal of Upstream Regulator Analysis in IPA is to identify upstream regulators of any given dataset and predict whether they are activated or inhibited given the observed gene expression changes. This analysis utilizes a Z score algorithm to make predictions. The Z score algorithm is designed to reduce the chance that random data will generate significant predictions. Upstream Regulator Analysis is derived from expected causal effects between upstream regulators and targets; the expected causal effects are based on the literature compiled and updated on a regular basis in the Ingenuity Knowledge Base.

*CFIm25* OE lentivirus construction and cell treatment {#s20}
------------------------------------------------------

*CFIm25* OE lentivirus vector was generated by cloning the CDS of human *CFIm25* into the pLV-EF1a-IRES-Puro Vector (Addgene) that contains an EF-1a promoter upstream of an IRES element to coexpress puromycin marker. *CFIm25* CDS were inserted between the EF-1a and IRES. The IRES allows the expression of CFIm25 and puromycin marker from a single mRNA, thus ensuring the coexpression of CFIm25 and puromycin marker in the same cells. The empty vector without any insertion was used as control. The *CFIm25*-overexpressing and control lentiviruses were then generated using the third-generation Lentivirus Packing System (Abm). The lentivirus titer was determined using the qPCR Lentivirus Titration (Titer) Kit (Abm). Human skin fibroblasts were transfected with *CFIm25* OE or control virus at a multiplicity of infection (MOI) of 25.

*CFIm25* OE in murine model of skin fibrosis {#s21}
--------------------------------------------

Another CFIm25-overexpressing lentivirus vector, pCMV-CFIm25-IRES-GFP, was generated by inserting the CFIm25 CDS into the PCIG3 (pCMV-IRES-GFP; Addgene) vector. PCIG3 vector without any insertion was used as control. These vectors replaced the puromycin gene with GFP gene, allowing us to track CFIm25 expression in vivo. Lentiviruses were generated using the second-generation lentivirus packing system (Addgene) to achieve higher titer. 6-wk-old female C57BL6 mice were s.c. injected with *CFIm25* OE or control lentivirus (50 μl 10 × 10^7^ PFU/ml at each spot) 1 wk before, 1 wk after, and 3 wk after initial bleomycin injection. Then, mice were injected with repeated s.c. bleomycin (0.02 U/mice/d, injected six times a week for 4 wk) starting 1 wk after the first lentivirus injection. Skin samples were collected on day 28 after the first bleomycin injection for analysis.

Sircol collagen assay {#s22}
---------------------

Fresh collected mouse skin were weighted and homogenized in 0.5 M acetic acid. For each milligram of mouse skin, 0.1 mg pepsin (Sigma-Aldrich) was added. Skin samples were rocked overnight at room temperature to release collagen. Digested skin samples were centrifuged and the supernatant was collected to determine the collagen concentration using the Sircol Soluble Collagen Assay kit (Biocolor). The final data were normalized to the wet skin weight.

Statistics {#s23}
----------

Results are expressed as the mean ± SEM. Data were analyzed using the Student's *t* test for comparison of two groups or ANOVA (GraphPad Software). The number of asterisks represents the degree of significance with respect to P value. P values \< 0.05 were considered significant.

Online supplemental material {#s24}
----------------------------

[Fig. S1](#figS1){ref-type="fig"} shows the number and percentage of CFIm25 and α-SMA stained cells in control and SSc skin, as well as the densitometry of Western blot showing CFIm25 and COL(I) expression in control and SSc skin. [Fig. S2](#figS2){ref-type="fig"} shows the densitometry analysis of the protein expression of fibrotic factors in normal HDFs with CFIm25 depletion. [Fig. S3](#figS3){ref-type="fig"} shows the densitometry analysis of CFIm25 and COL(I) protein expression in murine models of dermal fibrosis. [Fig. S4](#figS4){ref-type="fig"} shows the densitometry analysis of CFIm25 and fibrotic marker expression in the mouse skin samples with CFIm25 knockout. [Fig. S5](#figS5){ref-type="fig"} shows the densitometry analysis of CFIm25 and its targets expression in fibroblasts and mouse skin samples with CFIm25 OE. [Table S1](#tblS1){ref-type="table"} shows demographic and clinical characteristics of participants in the immunohistochemistry experiments. [Table S2](#tblS2){ref-type="table"} shows demographic and clinical characteristics of participants in the dPAS experiments. [Table S3](#tblS3){ref-type="table"} shows the primers used for RT-qPCR.

![***CFlm25* depletion induces upregulation of fibrotic factors in normal HDFs.** Five primary normal HDFs were transfected with *CFlm25*-specific siRNA (si_CFIm25) or a siRNA control (si_Con). Western blot were performed to confirmed effective *CFlm25* KD and increased protein levels of COL(I), TGFBR1, COL11A1, and SPARC. The densitometry of the Western blot was measured. Data are presented as mean (ratio to β-Actin) ± SEM and representative of three experiments with *n* = 5 cell lines per group. P values were determined using a paired two-tailed Student's *t* test comparing si_CFIm25 with si_Con. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181384_FigS2){#figS2}

![**CFIm25 protein levels are decreased in murine models of dermal fibrosis.** The densitometry of CFIm25 and COL(I) protein expression was determined in the skin lysate of (A) mice injected with PBS or bleomycin (*n* = 3 experiments with three or four mice per group) and (B) 8- to 10-wk-old WT and TSK1 mice (*n* = 2 experiments with six mice per group). COL(I) was used as a marker for fibrosis. Data are presented as mean (ratio to GAPDH) ± SEM. P values were determined using paired two-tailed Student\'s *t* test. \*, P \< 0.05; \*\*\*, P \< 0.001.](JEM_20181384_FigS3){#figS3}

![**Knocking out *CFIm25* in fibroblasts promotes dermal fibrosis.** 6- to 8-wk-old Col1a1-creER^T2^ and Col1a1-creER^T2^-*CFIm25*^f/f^ mice were treated with tamoxifen for 5 d to induce Cre activation. **(A)** Western blot was performed to determine Cre and CFIm25 expression in primary fibroblasts isolated from Col1a1-creER^T2^-*CFIm25*^f/f^ mice (*n* = 2 experiments with four mice per group). Densitometry of the Western blot was measured and data were normalized to GAPDH. **(B)** Western blot was performed to confirm the downregulation of *CFIm25* and the upregulation of fibrotic makers in skin of PBS/bleomycin-treated Col1a1-creER^T2^ and Col1a1-creER^T2^-*CFIm25*^f/f^ mice (*n* = 2 experiments with approximately five to eight mice per group). Densitometry of the Western blot was determined. Data are presented as mean (ratio to GAPDH) ± SEM. P values were determined using an unpaired two-tailed Student's *t* test. \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20181384_FigS4){#figS4}

![**CFIm25 OE attenuates fibrotic phenotype. (A)** Two HDFs were infected with control or *CFIm25*-overexpressing lentivirus at 25 MOI. Western blot was performed to confirm CFIm25 OE 2 d after the lentivirus infection and the expression of COL(I), TGFBR1, COL11A1, and SPARC 3 d after lentivirus infection. The densitometry of the Western blot image was quantified for each of the genes. **(B and C)** 6-wk-old mice were injected with s.c. GFP or CFIm25-IRES-GFP-overexpressing lentivirus (10 × 10^7^ PFU/ml, 50 µl per spot) 1 wk before, 1 wk after, and 3 wk after the initial bleomycin injection. Then mice were injected with repeated s.c. bleomycin six times a week for 4 wk. Skin was collected 28 d after the initial bleomycin injection. **(B)** Subsequently, the *CFIm25* transcript levels were determined. **(C)** The densitometry of the Western blot image was determined to quantify the expression of CFIm25, COL(I), fibronectin (FN), TGFBR1, COL11A1, and SPARC. Data are presented as mean ± SEM for *n* = 3 experiments and two cell lines per group (A) or *n* = 2 experiments and five mice per group (B and C). P values were determined using an unpaired two-tailed Student's *t* test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20181384_FigS5){#figS5}
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